Skip to main content
ASND
NASDAQ Life Sciences

关键试验显示TransCon CNP在软骨发育不全症中具有可持续的两年益处

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$229.01
Mkt Cap
$13.871B
52W Low
$124.06
52W High
$248.6
Market data snapshot near publication time

summarizeSummary

Ascendis Pharma宣布其关键的ApproaCH试验中关于TransCon CNP（navepegritide）的新两年数据，后者被作为YUVIWEL®在软骨发育不全症儿童中销售。数据表明，在第104周，生长和身体比例方面有持续的改善，药物一般耐受性良好。这种积极的长期疗效和安全性数据加强了YUVIWEL的商业化特征，YUVIWEL于2026年2月获得了美国FDA的批准。这种可持续的益处对于医生的信心和市场采纳至关重要，也支持正在进行的欧洲药品管理局审查，预计在2026年第四季度做出决定。交易者将关注欧洲批准和美国初期销售动态的更新。

在该公告发布时，ASND的交易价格为$229.01，交易所为NASDAQ，所属行业为Life Sciences，市值约为$138.7亿。 52周交易区间为$124.06至$248.60。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed ASND - Latest Insights

ASND
Apr 21, 2026, 5:16 PM EDT
Filing Type: 6-K
Importance Score:
8
Ascendis Pharma Calls $575M Convertible Notes for Redemption, Potential for Significant Share Dilution
Sentiment: Neutral
View Wiseek Article
ASND
Apr 20, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
7
Ascendis Pharma Completes Transition to Direct Nasdaq Listing for Ordinary Shares
Sentiment: Positive
View Wiseek Article
ASND
Apr 08, 2026, 4:02 PM EDT
Filing Type: 6-K
Importance Score:
7
Ascendis Pharma to Directly List Ordinary Shares on Nasdaq, Mandating ADS Exchange
Sentiment: Neutral
View Wiseek Article
ASND
Apr 08, 2026, 8:01 AM EDT
Source: GlobeNewswire
Importance Score:
9
Achondroplasia Combo Therapy Shows Unprecedented Non-Linear Growth Benefits in Ascendis Pharma Trial
Sentiment: Positive
View Wiseek Article
ASND
Apr 07, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
FDA Grants Orphan Drug Exclusivity for YUVIWEL, Now Commercially Available in US
Sentiment: Positive
View Wiseek Article
ASND
Apr 06, 2026, 4:13 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Yuviwel Gains 7-Year U.S. Orphan Drug Exclusivity for Ascendis Pharma
Sentiment: Positive
View Wiseek Article
ASND
Mar 17, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Ascendis Pharma Reports Positive Phase 2 Results for TransCon hGH in Turner Syndrome
Sentiment: Positive
View Wiseek Article
ASND
Mar 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Ascendis Pharma's Once-Weekly Growth Hormone Matches Daily Therapy in Turner Syndrome Trial
Sentiment: Positive
View Wiseek Article
ASND
Mar 16, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Ascendis Pharma Reports Strong Two-Year Data for Approved Achondroplasia Drug TransCon CNP
Sentiment: Positive
View Wiseek Article
ASND
Mar 16, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Pivotal Trial Shows TransCon CNP's Durable Two-Year Benefits in Achondroplasia
Sentiment: Positive
View Wiseek Article